Tislelizumab Plus Chemotherapy as First-Line Tx Improves PFS

Treatment with tislelizumab plus chemotherapy achieved prolonged progression-free survival (PFS) for recurrent or metastatic nasopharyngeal cancer (RM-NPC).

Related Keywords

China , Yunpeng Yang , Oncology Esmoio Congress , European Society For Medical Oncology Immuno , Professor At Sun Yat Sen University Cancer Center , European Society , Medical Oncology Immuno , Independent Review Committee , Sun Yat Sen University Cancer Center ,